Theravance Biopharma, Inc. (TBPH)
NASDAQ: TBPH · Real-Time Price · USD
18.55
-0.15 (-0.80%)
At close: Dec 5, 2025, 4:00 PM EST
19.59
+1.04 (5.61%)
After-hours: Dec 5, 2025, 5:40 PM EST
Theravance Biopharma Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Theravance Biopharma stock have an average target of 27.8, with a low estimate of 20 and a high estimate of 40. The average target predicts an increase of 49.87% from the current stock price of 18.55.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Theravance Biopharma stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 4 | 4 | 4 | 4 |
| Buy | 0 | 0 | 0 | 0 | 0 | 1 |
| Hold | 2 | 2 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 4 | 4 | 4 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Oppenheimer | Oppenheimer | Buy Initiates $27 | Buy | Initiates | $27 | +45.55% | Dec 3, 2025 |
| BTIG | BTIG | Strong Buy Maintains $25 → $40 | Strong Buy | Maintains | $25 → $40 | +115.63% | Nov 26, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $15 → $20 | Strong Buy | Maintains | $15 → $20 | +7.82% | Nov 11, 2025 |
| B. Riley Securities | B. Riley Securities | Strong Buy Initiates $28 | Strong Buy | Initiates | $28 | +50.94% | Sep 12, 2025 |
| BTIG | BTIG | Strong Buy Maintains $24 → $25 | Strong Buy | Maintains | $24 → $25 | +34.77% | Jun 27, 2025 |
Financial Forecast
Revenue This Year
109.95M
from 64.38M
Increased by 70.78%
Revenue Next Year
88.60M
from 109.95M
Decreased by -19.42%
EPS This Year
1.92
from -1.15
EPS Next Year
0.96
from 1.92
Decreased by -49.69%
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 114.0M | 100.6M | ||||
| Avg | 110.0M | 88.6M | ||||
| Low | 105.1M | 80.4M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 77.1% | -8.5% | ||||
| Avg | 70.8% | -19.4% | ||||
| Low | 63.2% | -26.9% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 2.36 | 1.37 | ||||
| Avg | 1.92 | 0.96 | ||||
| Low | 1.37 | 0.19 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | -28.8% | ||||
| Avg | - | -49.7% | ||||
| Low | - | -90.3% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.